Moffitt at ASH
The 64th installment of the American Society of Hematology (ASH) Annual Meeting was held at the Ernest N. Morial Convention Center in New Orleans, Louisiana, December 10-13, 2022.
Moffitt's nationally lauded Malignant Hematology Program specializes in the diagnosis and treatment of blood cancers and autoimmune disorders, and we are dedicated to providing exceptional care by developing a tailored treatment plan for each patient. This year, Moffitt authors were listed on 156 abstracts that showcased the latest advances in hematology. In total, there were 57 oral and poster presentations presented by Moffitt authors, three scientific symposia featuring Moffitt speakers.
To learn more about Moffitt's research and breakthroughs, follow Moffitt on Twitter (@MoffittNews) and LinkedIn or subscribe to our newsletters.
2022 Featured Articles
Moffitt Investigates First-of-Its-Kind Cellular Therapy in MDS Patients
Novel approach uses mismatched donor lymphocytes to activate patient’s immune system
Donor CAR T May Increase Remission in Relapsed or Refractory AML Patients
Good clinical responses seen for using genetically modified product
New Therapy Shows Promise for Myelodysplastic Syndrome Patients
SX-682 works by targeting both adverse immune cells and cancer cells
Study Highlights Potential Disparities for CAR T Patients with Multiple Myeloma
Potential racial and ethnic disparities among patients that received CAR T therapy
For additional information on Moffitt’s research presented at ASH please reach out to:
Kim Polacek, APR, CPRC
Senior PR Account Coordinator
Meet the Malignant Hematology Team
Our malignant hematology specialists have a unique level of experience treating patients.
Meet the BMT & Cellular Immunotherapy Team
Due to the specialization of our team, we are able to achieve exceptional outcomes for our patients.
Diversity, Equity and Inclusion
The diversity of our employees and communities is valued and supported as essential components to contributing to the prevention and cure of cancer.
With our robust portfolio of clinical trials, Moffitt remains firmly established at the forefront of cancer research.
Cell Therapies Core
The Cell Therapies Core provides service to members to facilitate translation of promising therapies for cancer patients.
Physician Liaison Team
Our goal is to forge partnerships with healthcare professionals to improve patient access and outcomes.